Forskning 2007 - Herlev Hospital

herlevhospital.dk

Forskning 2007 - Herlev Hospital

Forskning 2007

Hæmatologisk Afdeling L

Forskningsområder

Cellebiologisk og –genetisk forskning, baseret på flow

cytometri.

Patogeneseforskning, baseret på genetiske undersøgelser

af stamceller.

Stamcelleforskning med henblik på optimering af

autologe transplantationer ved kræftsygdomme.

Basal tumorimmunologi og immunterapi af maligne

lidelser.

Klinisk afprøvning af ny medicin og nye behandlingsprincipper.

Klinisk implementering af nye diagnostiske og prognostiske

metoder.

Forskningsaktiviteter

Benigne og maligne hæmatologiske sygdomme med

fokus på implementering af nye laboratorieteknikker

i klinisk sammenhæng, dvs. ved diagnostik, prognostik

og terapi.

Det drejer sig om følgende sygdomme:

1) hæmoglobinopatier, 2) kræftsygdommene myelomatose,

leukæmi og lymfomer og 3) basal tumorimmunologi

og immunterapi af solid cancer såvel som maligne

hæmatologiske lidelser.

Originalartikler

Andersen MH, Svane IM, Becker JC, Straten PT. The

universal character of the tumour-associated antigen

survivin. Clin Cancer Res 2007;13(20):5991-4.

Birgens H, Ljung R. The thalassaemia syndromes. Scandinavian

Journal of Clinical & Laboratory Investigation

2007;67(1):11-25.

Cocks K, Cohen D, Wisloff F, Sezerc O, Lee S, Hippe E,

Gimsing P, Turesson I, Hajek R, Smith A, Graham L,

Phillips A, Stead M, Velikova G, Brown J. An internadional

field study of the reliability and validity of a

disease-specfic questionnanire module (the QLQ-MY20)

in assessing the quality of life of patients with multiple

myeloma. Eur J Cancer 2007;43(11):1670-8.

Dorn T, Kuhn U, Bungartz G, Stiller S, Bauer M, Ellwart

J, Peters T, Scharffetter-Kochanek K, Semmrich M,

Laschinger M, Holzmann B, Klinkert WEF, Straten PT,

Kollgaard T, Sixt M, Brakebusch C. RhoH is important

for positive thymocyte selection and T-cell receptor

signaling. Blood 2007;109(6):2346-55.

Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard

BG. Hemochromatosis genotypes and risk of 31 disease

endpoints: Meta-analyses including 66,000 cases and

226,000 controls. Hepatology 2007;46(4):1071-80.

Hansen PB, Jensen MK. Primaere non-Hodgkin-lymfomer

i centralnervesystemet. Stadig flere sporgsmal

end svar i behandlingen? Ugeskrift for laeger 2007 Jun

4;169(23):2187-9.

Kaae J, Norgaard P, Himmelstrup B. Visceral leishmaniasis

diagnosed in a patient with MALT lymphoma. European

Journal of Internal Medicine 2007;18(3):235-7.

Kornblit B, Hagve TA, Taaning P, Birgens H. Phenotypic

presentation and underlying mutations in carriers of

beta-thalassaemia and alpha-thalassaemia in the Danish

immigrant population. Scandinavian Journal of Clinical

& Laboratory Investigation 2007;67(1):97-104.

Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D,

Lemonnier FA, Straten PT, Mueller L, Rees RC, Mcardle

SEB. HAGE, a cancer/testis antigen with potential for

melanoma immunotherapy: identification of several

MHC class I/II HAGE-derived immunogenic peptides. Cancer

Immunology Immunotherapy 2007;56(12):1885-95.

Petersen J, Stangegaard M, Birgens H, Dufva M. Detection

of mutations in the beta-globin gene by colorimetric

staining of DNA microarrays visualized by a flatbed

scanner. Anal Biochem 2007;360(1):169-71.

Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Lodahl

M, Rasmussen T. Dysregulation of CD47 and the

ligands thrombospondin 1 and 2 in multiple myeloma.

Br J Haematol 2007 Sep;138(6):756-60.

Sorensen RB, Hadrup SR, Kollgaard T, Svane IM,

Straten PT, Andersen MH. Efficient tumor cell lysis

mediated by a Bcl-X(L) specific T cell clone isolated from

a breast cancer patient. Cancer Immunology Immunotherapy

2007;56(4):527-33.

Svane IM, Nikolajsen K, Johnsen HE. Antigen-specific

T-cell immunity in multiple myeloma patients is restored

following high-dose therapy: Implications for timing

of vaccination. Scand J Immunol 2007;66(4):465-75.

Svane IM, Pedersen AE, Johansen JS, Johnsen HE,

Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal

E, Nikolajsen K, Claesson MH. Vaccination with p53

peptide-pulsed dendritic cells is associated with disease

stabilization in patients with p53 expressing advanced

breast cancer; monitoring of serum YKL-40 and IL-6 as

response biomarkers. Cancer Immunology Immunotherapy

2007;56(9):1485-99.

Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin

23

More magazines by this user
Similar magazines